1.89
+1.07%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medicus Pharma
From its filings with the US Securities and Exchange Commission
Medicus Pharma is based in W. Conshohocken, Pennsylvania and is incorporated in Ontario, Canada. Its shares trade on Nasdaq under the ticker MDCX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $47.3m. At that date it held total assets of $10.1m and shareholders' equity of −$67,554.
Our company (formerly, Interactive Capital Partners Corporation) was incorporated pursuant to the Business Corporations Act (Ontario) on April 30, 2008 under the name Interactive Capital Partners Corporation.
On October 11, 2023, the Company's common shares commenced trading on the TSX Venture Exchange (the "TSXV") under the symbol "MDCX". On November 15, 2024, we completed our initial public offering in the United States and our common shares and our outstanding public warrants to purchase common shares, issued as a component of the units sold by the Company in its U.S. initial public offering with an exercise price of $4.64 and expiration date of November 15, 2029 (the "Public Warrants"), began trading on Nasdaq under the symbols "MDCX" and "MDCXW", respectively. Effective on February 21, 2025, the Company's common shares were voluntarily delisted from the TSXV. The common shares continue to be listed on Nasdaq.
On August 29, 2025, we completed the acquisition of 98.6% of the issued and outstanding shares of Antev for aggregate consideration consisting of approximately US$2.97 million in cash and 1,603,164 common shares of Medicus, pursuant to a securities exchange agreement among Medicus, Antev and certain securityholders of Antev, dated as of June 29, 2025, as amended. The share-based consideration was subject to staggered release from escrow.
Quoted from its 10-K, filed 25 Mar 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 11 Oct 2023
- Head office
- 300 CONSHOHOCKEN STATE RD., W. CONSHOHOCKEN, PA, 19428
- Incorporated in
- A6
- Classification
- Pharmaceutical Preparations
- Filer status
- <br>Emerging growth company
Leadership
Pay as last reported
- Dr. Raza BokhariExecutive Chairman, of the Board, Chief Executive Officer, since 2023
- Ms. Carolyn BonnerPresident, Acting Chief Financial Officer
- Mr. Andrew SmithChief Operating Officer
- Dr. Edward BrennanChief Scientific Officer, Head of Research and Development ProgramC$204,241
- Dr. Faisal MehmudChief Medical Officer
- Mr. Robert CiaruffoliLead Independent DirectorC$24,799
- Mr. Patrick MahaffyDirector
- Dr. Sara MayDirector
- Mr. William AshtonIndependent DirectorC$16,533
- Mr. Barry FishmanIndependent DirectorC$19,839
- Dr. Larry KaiserIndependent DirectorC$19,839
- Mr. Frank LavelleIndependent DirectorC$19,839
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Medicus Pharma Ltd operates as a clinical stage holding company in Canada.
- The firm advances de-risked assets through FDA approved clinical trials.
- SkinJect offers a novel dissolvable microneedle array for skin cancer treatment.
Weaknesses
- The company is a clinical stage firm with limited commercial history.
- Medicus Pharma relies on acquiring assets rather than internal discovery.
- SkinJect targets only common non-melanoma skin cancer forms currently.
Opportunities
- The firm plans to expand its drug development pipeline via acquisitions.
- Partnerships could accelerate the commercialization of SkinJect technology globally.
- FDA approval pathways offer potential for rapid market entry.
Threats
- Competitors may develop superior dissolvable microneedle array technologies.
- Regulatory hurdles in FDA approved clinical trials pose delays.
- Market adoption of minimally invasive treatments remains uncertain.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.